April 17th Options Now Available For Medtronic (MDT)

Stock Options Channel highlights option strategies for Medtronic (MDT, $98.40): selling the $92.50 put (bid $0.36) nets a $92.14 effective cost basis, about a 6% discount to current price, with a 72% chance to expire worthless and a 0.39% return (1.54% annualized) if it does. A covered call at the $100 strike (bid $2.05) would yield 3.71% total return to expiration if called, with the strike ~2% above the current price and a 53% chance to expire worthless, representing a 2.08% YieldBoost (8.27% annualized). Implied volatilities are 24% for the put and 22% for the call versus a 12-month trailing volatility of 21%.

Analysis

Market structure: Option-income strategies (cash-secured put sellers and covered-call sellers) directly benefit—they harvest yield (0.39% cash-secured put yield to expiry, 2.08% covered-call premium) and absorb stock exposure if assigned. Active retail/institutional income flows into MDT options can compress implied vol from current 22–24% toward realized ~21%, modestly tightening OTC skew and leaving limited short-gamma risk for option sellers through the April 17 expiry (~1 month). The company itself is neutral; hospitals/elective procedure volumes drive demand for devices and are the ultimate demand lever.

Risk assessment: Tail risks include an FDA recall, a large product liability judgment, or a macro hit to elective procedures that could drop MDT >10% in weeks — these would invalidate income trades and spike IV >35%. Near-term (days–weeks) risks center on IV movement and earnings/FDA calendar; medium-term (1–3 months) outcome hinges on procedure volumes and supply-chain cadence; long-term (quarters) depends on product cadence and M&A. Hidden dependencies: assignment timing, dividend/ex-date adjustments and capital-routering for cash-secured puts that tie up cash returns.

Trade implications: Direct plays — prefer cash-secured put at $92.50 (sell-to-open) or buy-and-covered-call at $100 to capture defined short-term yield; size modestly (1–3% per trade) and treat as accumulation strategies rather than directional bets. Use protective put spreads (e.g., Apr17 90/85) or collars if writing premium at scale; watch IV vs realized (act if IV premium >3 pts above realized). Relative ideas: overweight MDT vs SYK/BSX if you expect steadier recurring-revenue growth and better margin resilience.

Contrarian angles: Consensus underestimates assignment optionality — sellers often end up long at ~92.14 basis, so these are structured accumulation trades, not pure yield plays. The annualized YieldBoosts (1.54% vs 8.27%) overstate attractiveness for short durations; mispricing exists if IV compresses post-earnings—sell premium only after confirming no material catalysts in next 30 days. Historical parallel: medtech pullbacks on recalls have mean reversion over 6–12 months; position size and protective collars matter more than short-term yield capture.

Key Decisions for Investors

• Establish a cash-secured put position: sell MDT Apr17 $92.50 puts (collect ~$0.36) sized to 1–2% of portfolio exposure, with rule-based management: close/roll if MDT < $88 or implied vol >35% or the probability of expiring worthless falls below 50%.
• Implement a covered-call accumulation: buy MDT up to 2–3% portfolio weight and sell Apr17 $100 calls (collect ~$2.05), target total return ~3.7% to expiry; buy back/roll if MDT trades >$104 or on material positive catalyst to retain upside.
• Hedge material tail risk when scaling premium strategies: purchase an Apr17 MDT 90/85 put spread sized at 25–50% of written notional (cost-limited protection) if aggregate written premium exposure >3% portfolio.
• Relative-value trade: go long MDT and short SYK (equal dollar, 0.5–1% net exposure) for 3–6 months, expecting MDT to outperform on recurring revenue stability; exit if relative performance reverses by 5% or after 6 months.